DeuterOncology
The computed 12-month bankruptcy probability of DeuterOncology is 1.6% (moderate). The 2024 annual accounts show equity of €966k and a net result of €-2.11M. Equity is growing by ~34.6% per year across the filed fiscal years. Its solvency ranks better than 75% of 46 sector peers (fiscal year 2024). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €966k |
| Net result | €-2.11M |
| Better than sector | 75% |
| Active | 5 yrs |
Strong profile, led by solvency.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 76.0% | 46.9% | |
| Net result | €-2.11M | €-1k | |
| Equity | €966k | €108k | |
| Gross operating margin | €-1.99M | €28k | |
| Total assets | €1.27M | €284k |
Show 10 other metrics
| Fiscal year | 2024 |
|---|---|
| Deposit | volledig |
| Revenue | - |
| EBITDA | €-1.99M |
| Net profit | €-2.11M |
| Cash flow | €-1.81M |
| Staff costs | - |
| Income taxes | €-12k |
| Dividends | - |
| Total assets | €1.27M |
| Equity | €966k |
| Debt | €306k |
| of which ≤ 1y | €304k |
| of which > 1y | - |
| Working capital | €735k |
| Employees (FTE) | 0.0 |
| 2024 | |
|---|---|
| Current ratio | 3.41 |
| Quick ratio | 3.41 |
| Working capital ratio | 57.8% |
| Solvency | 76.0% |
| Debt / equity | 0.32 |
| Long-term debt ratio | - |
| Interest coverage | -754.29 |
| Gross margin | - |
| Net margin | - |
| ROA | -166.4% |
| ROE | -219.0% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | 48d |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts (22 line items)
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €1.27M |
| Fixed assets | 21/28 | €232k |
| Intangible fixed assets | 21 | €2k |
| Financial fixed assets | 28 | €230k |
| Current assets | 29/58 | €1.04M |
| Amounts receivable within one year | 40/41 | €172k |
| Cash & bank | 54/58 | €829k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €1.27M |
| Equity | 10/15 | €966k |
| Contributions / capital | 10/11 | €8.60M |
| Accumulated profits (losses) | 14 | €-7.63M |
| Amounts payable | 17/49 | €306k |
| Amounts payable within one year | 42/48 | €304k |
| Trade debts payable within one year | 44 | €304k |
| Income statement | ||
| Gross operating margin | 9900 | €-1.99M |
| Operating result | 9901 | €-2.29M |
| Financial income | 75 | €165k |
| Financial charges | 65 | €3k |
| Result before taxes | 9903 | €-2.13M |
| Income taxes | 67/77 | €-12k |
| Net result for the period | 9904 | €-2.11M |
| Result to be appropriated | 9905 | €-2.11M |
-
Current12-05-2026 → present
-
Newton Biocapital Partners BVLegal entityDirector· perm. rep.: Jean CombalbertState Gazette act 25092346 (22-07-2025)Current01-06-2024 → present
-
Current01-03-2021 → present
-
VIZIPHAR Biosciences BVLegal entityDirector· perm. rep.: Gustaaf Van ReetState Gazette act 21041759 (06-04-2021)Current01-03-2021 → present
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISESCurrent Statutory auditor · represented by Veerle Catry |
- | 26-09-2023 → present |
| NACE primary | Vervaardiging van farmaceutische grondstoffen(21100) |
| Legal form | Public limited company(014) |
| Incorporation | 28-09-2020 |
| Status | Active |
| Postal code | 4000 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62078A0391/00K002 | Wallonia | 2,138 m² | 1 · 426 m² | - |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
We know of 12 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
12-05-2026 Officer resignation · Officer appointment · Power of attorney · Act object
- Filing: 2026-04-30 · DeuterOncology
- Publication: 2026-05-12 · DeuterOncology
- Officer resignation: date: 2026-03-27, role: président du conseil d'administration, effective: immédiat · VIZIPHAR Biosciences SRL
- Officer appointment: date: 2026-03-27, role: président du conseil d'administration, duration: durée indéterminée, effective: immédiat · Huerga Sanchez Iker
- Power of attorney: date: 2026-03-27, purpose: publier les présentes décisions dans les annexes au Moniteur belge et de remplir toute les formalités relatives à la modification de l'inscription de la Société dans la Banque-carrefour des entreprises et auprès de l'administration de la TVA et à cet effet, signer toute pièce et tout acte, y compris les formulaires de publication et les formulaires spéciaux à transmettre aux guichets d'entreprises., granted_by: conseil d'administration · DeuterOncology
- Power of attorney: date: 2026-03-27, purpose: publier les présentes décisions dans les annexes au Moniteur belge et de remplir toute les formalités relatives à la modification de l'inscription de la Société dans la Banque-carrefour des entreprises et auprès de l'administration de la TVA et à cet effet, signer toute pièce et tout acte, y compris les formulaires de publication et les formulaires spéciaux à transmettre aux guichets d'entreprises., granted_by: conseil d'administration · DeuterOncology
- Power of attorney: date: 2026-03-27, purpose: publier les présentes décisions dans les annexes au Moniteur belge et de remplir toute les formalités relatives à la modification de l'inscription de la Société dans la Banque-carrefour des entreprises et auprès de l'administration de la TVA et à cet effet, signer toute pièce et tout acte, y compris les formulaires de publication et les formulaires spéciaux à transmettre aux guichets d'entreprises., granted_by: conseil d'administration · DeuterOncology
- Power of attorney: date: 2026-03-27, purpose: publier les présentes décisions dans les annexes au Moniteur belge et de remplir toute les formalités relatives à la modification de l'inscription de la Société dans la Banque-carrefour des entreprises et auprès de l'administration de la TVA et à cet effet, signer toute pièce et tout acte, y compris les formulaires de publication et les formulaires spéciaux à transmettre aux guichets d'entreprises., granted_by: conseil d'administration · DeuterOncology
- Act object: Démission et nomination du président du conseil d'administration
Technical details
{
"facts": [
{
"type": "filing",
"quote": "30 AVR. 2026",
"value": "2026-04-30",
"object": null,
"subject": "e1"
},
{
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 12/05/2026",
"value": "2026-05-12",
"object": null,
"subject": "e1"
},
{
"type": "officer_resignation",
"quote": "prendre acte de la d\u00E9mission de VIZIPHAR Biosciences SRL (num\u00E9ro d\u0027entreprise 0862.727.797), ayant son si\u00E8ge \u00E0 Populierenlaan 14, 2460 Kasterlee, repr\u00E9sent\u00E9 par Van Reet Gustaaf, en tant que pr\u00E9sident du conseil d\u0027administration avec effet imm\u00E9diat.",
"value": {
"date": "2026-03-27",
"role": "pr\u00E9sident du conseil d\u0027administration",
"effective": "imm\u00E9diat"
},
"object": "e1",
"subject": "e2"
},
{
"type": "officer_appointment",
"quote": "nommer Huerga Sanchez Iker en tant que pr\u00E9sident du conseil d\u0027administration, avec effet imm\u00E9diat et pour une dur\u00E9e ind\u00E9termin\u00E9e.",
"value": {
"date": "2026-03-27",
"role": "pr\u00E9sident du conseil d\u0027administration",
"duration": "dur\u00E9e ind\u00E9termin\u00E9e",
"effective": "imm\u00E9diat"
},
"object": "e1",
"subject": "e4"
},
{
"type": "power_of_attorney",
"quote": "Un pouvoir sp\u00E9cial est donn\u00E9 \u00E0 Christoph Michiels, Enkeleta Fazliu, Nicolas Bosschaerts et Anthea Debou, collaborateurs du cabinet d\u0027avocats Deloitte Legal - Lawyers, qui, \u00E0 cet effet \u00E9lisent domicile \u00E0 Gateway building, 1930 Zaventem, Luchthaven Brussel Nationaal 1 J, agissant s\u00E9par\u00E9ment, afin de publier les pr\u00E9sentes d\u00E9cisions dans les annexes au Moniteur belge et de remplir toute les formalit\u00E9s relatives \u00E0 la modification de l\u0027inscription de la Soci\u00E9t\u00E9 dans la Banque-carrefour des entreprises et aupr\u00E8s de l\u0027administration de la TVA et \u00E0 cet effet, signer toute pi\u00E8ce et tout acte, y compris les formulaires de publication et les formulaires sp\u00E9ciaux \u00E0 transmettre aux guichets d\u0027entreprises.",
"value": {
"date": "2026-03-27",
"purpose": "publier les pr\u00E9sentes d\u00E9cisions dans les annexes au Moniteur belge et de remplir toute les formalit\u00E9s relatives \u00E0 la modification de l\u0027inscription de la Soci\u00E9t\u00E9 dans la Banque-carrefour des entreprises et aupr\u00E8s de l\u0027administration de la TVA et \u00E0 cet effet, signer toute pi\u00E8ce et tout acte, y compris les formulaires de publication et les formulaires sp\u00E9ciaux \u00E0 transmettre aux guichets d\u0027entreprises.",
"granted_by": "conseil d\u0027administration"
},
"object": "e5",
"subject": "e1"
},
{
"type": "power_of_attorney",
"quote": "Un pouvoir sp\u00E9cial est donn\u00E9 \u00E0 Christoph Michiels, Enkeleta Fazliu, Nicolas Bosschaerts et Anthea Debou, collaborateurs du cabinet d\u0027avocats Deloitte Legal - Lawyers, qui, \u00E0 cet effet \u00E9lisent domicile \u00E0 Gateway building, 1930 Zaventem, Luchthaven Brussel Nationaal 1 J, agissant s\u00E9par\u00E9ment, afin de publier les pr\u00E9sentes d\u00E9cisions dans les annexes au Moniteur belge et de remplir toute les formalit\u00E9s relatives \u00E0 la modification de l\u0027inscription de la Soci\u00E9t\u00E9 dans la Banque-carrefour des entreprises et aupr\u00E8s de l\u0027administration de la TVA et \u00E0 cet effet, signer toute pi\u00E8ce et tout acte, y compris les formulaires de publication et les formulaires sp\u00E9ciaux \u00E0 transmettre aux guichets d\u0027entreprises.",
"value": {
"date": "2026-03-27",
"purpose": "publier les pr\u00E9sentes d\u00E9cisions dans les annexes au Moniteur belge et de remplir toute les formalit\u00E9s relatives \u00E0 la modification de l\u0027inscription de la Soci\u00E9t\u00E9 dans la Banque-carrefour des entreprises et aupr\u00E8s de l\u0027administration de la TVA et \u00E0 cet effet, signer toute pi\u00E8ce et tout acte, y compris les formulaires de publication et les formulaires sp\u00E9ciaux \u00E0 transmettre aux guichets d\u0027entreprises.",
"granted_by": "conseil d\u0027administration"
},
"object": "e6",
"subject": "e1"
},
{
"type": "power_of_attorney",
"quote": "Un pouvoir sp\u00E9cial est donn\u00E9 \u00E0 Christoph Michiels, Enkeleta Fazliu, Nicolas Bosschaerts et Anthea Debou, collaborateurs du cabinet d\u0027avocats Deloitte Legal - Lawyers, qui, \u00E0 cet effet \u00E9lisent domicile \u00E0 Gateway building, 1930 Zaventem, Luchthaven Brussel Nationaal 1 J, agissant s\u00E9par\u00E9ment, afin de publier les pr\u00E9sentes d\u00E9cisions dans les annexes au Moniteur belge et de remplir toute les formalit\u00E9s relatives \u00E0 la modification de l\u0027inscription de la Soci\u00E9t\u00E9 dans la Banque-carrefour des entreprises et aupr\u00E8s de l\u0027administration de la TVA et \u00E0 cet effet, signer toute pi\u00E8ce et tout acte, y compris les formulaires de publication et les formulaires sp\u00E9ciaux \u00E0 transmettre aux guichets d\u0027entreprises.",
"value": {
"date": "2026-03-27",
"purpose": "publier les pr\u00E9sentes d\u00E9cisions dans les annexes au Moniteur belge et de remplir toute les formalit\u00E9s relatives \u00E0 la modification de l\u0027inscription de la Soci\u00E9t\u00E9 dans la Banque-carrefour des entreprises et aupr\u00E8s de l\u0027administration de la TVA et \u00E0 cet effet, signer toute pi\u00E8ce et tout acte, y compris les formulaires de publication et les formulaires sp\u00E9ciaux \u00E0 transmettre aux guichets d\u0027entreprises.",
"granted_by": "conseil d\u0027administration"
},
"object": "e7",
"subject": "e1"
},
{
"type": "power_of_attorney",
"quote": "Un pouvoir sp\u00E9cial est donn\u00E9 \u00E0 Christoph Michiels, Enkeleta Fazliu, Nicolas Bosschaerts et Anthea Debou, collaborateurs du cabinet d\u0027avocats Deloitte Legal - Lawyers, qui, \u00E0 cet effet \u00E9lisent domicile \u00E0 Gateway building, 1930 Zaventem, Luchthaven Brussel Nationaal 1 J, agissant s\u00E9par\u00E9ment, afin de publier les pr\u00E9sentes d\u00E9cisions dans les annexes au Moniteur belge et de remplir toute les formalit\u00E9s relatives \u00E0 la modification de l\u0027inscription de la Soci\u00E9t\u00E9 dans la Banque-carrefour des entreprises et aupr\u00E8s de l\u0027administration de la TVA et \u00E0 cet effet, signer toute pi\u00E8ce et tout acte, y compris les formulaires de publication et les formulaires sp\u00E9ciaux \u00E0 transmettre aux guichets d\u0027entreprises.",
"value": {
"date": "2026-03-27",
"purpose": "publier les pr\u00E9sentes d\u00E9cisions dans les annexes au Moniteur belge et de remplir toute les formalit\u00E9s relatives \u00E0 la modification de l\u0027inscription de la Soci\u00E9t\u00E9 dans la Banque-carrefour des entreprises et aupr\u00E8s de l\u0027administration de la TVA et \u00E0 cet effet, signer toute pi\u00E8ce et tout acte, y compris les formulaires de publication et les formulaires sp\u00E9ciaux \u00E0 transmettre aux guichets d\u0027entreprises.",
"granted_by": "conseil d\u0027administration"
},
"object": "e8",
"subject": "e1"
},
{
"type": "act_object",
"quote": "Objet de l\u0027acte: D\u00E9mission et nomination du pr\u00E9sident du conseil d\u0027administration",
"value": "D\u00E9mission et nomination du pr\u00E9sident du conseil d\u0027administration",
"object": null,
"subject": null
}
],
"act_meta": {
"model_id": 40,
"extractor": "open-capture-27b-v3",
"ocr_chars": 2127,
"truncated": false,
"needs_verify": false
},
"entities": [
{
"id": "e1",
"kbo": "0754.971.388",
"kind": "company",
"name": "DeuterOncology",
"attrs": {
"address": "Clos Chanmurly 13, 4000 Li\u00E8ge",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"short_name": "Mod DOC 19.01"
}
},
{
"id": "e2",
"kbo": "0862.727.797",
"kind": "company",
"name": "VIZIPHAR Biosciences SRL",
"attrs": {
"address": "Populierenlaan 14, 2460 Kasterlee"
}
},
{
"id": "e3",
"kbo": null,
"kind": "person",
"name": "Van Reet Gustaaf",
"attrs": {}
},
{
"id": "e4",
"kbo": null,
"kind": "person",
"name": "Huerga Sanchez Iker",
"attrs": {}
},
{
"id": "e5",
"kbo": null,
"kind": "person",
"name": "Christoph Michiels",
"attrs": {}
},
{
"id": "e6",
"kbo": null,
"kind": "person",
"name": "Enkeleta Fazliu",
"attrs": {}
},
{
"id": "e7",
"kbo": null,
"kind": "person",
"name": "Nicolas Bosschaerts",
"attrs": {}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "Anthea Debou",
"attrs": {}
},
{
"id": "e9",
"kbo": null,
"kind": "org",
"name": "Deloitte Legal - Lawyers",
"attrs": {
"address": "Gateway building, 1930 Zaventem, Luchthaven Brussel Nationaal 1 J"
}
}
]
}08-04-2026 Articles of association amended, translation of the articles, coordination of the articles and full restatement of the articles
Technical details
{
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": "BERQUIN NOTAIRES",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "mixed",
"pub_date": "2026-04-08",
"filing_date": "2026-04-03",
"act_kind_objet": "CAPITAL, ACTIONS, DEMISSIONS, NOMINATIONS, STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS)"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2026-03-27",
"unanimous": true
},
"statute_change": {
"kinds": [
"translation",
"coordination",
"full_restatement",
"legal_form_change",
"wvv_adaptation",
"name_change",
"object_change",
"duration_change",
"share_split",
"share_consolidation",
"share_class_creation",
"board_authorized_capital",
"governance_restructure",
"liquidation_preference_introduction",
"seat_region_change"
],
"scope": "full_restatement",
"trigger": "wvv_adaptation",
"language_after": "bilingual",
"language_before": "bilingual"
},
"bedrijfsrevisor": {
"firm_kbo": null,
"firm_name": "BDO BEDRIJFSREVISOREN-BDO REVISEURS D\u2019ENTREPRISES",
"ibr_number": null,
"individual_name": "Veerle Catry"
},
"subject_company": {
"kbo": "0754.971.388",
"name_full_after": "DeuterOncology",
"legal_form_after": "Soci\u00E9t\u00E9 anonyme",
"name_full_before": "DeuterOncology",
"current_zetel_raw": "Clos Chanmurly 13 4000 Li\u00E8ge",
"legal_form_before": "Soci\u00E9t\u00E9 anonyme"
},
"special_mandates": [
{
"holder_kbo": null,
"holder_name": "Berquin Notarissen BV/SRL",
"scope_categories": [
"publication"
],
"with_substitution": true
},
{
"holder_kbo": null,
"holder_name": "Christoph Michiels",
"scope_categories": [
"publication"
],
"with_substitution": true
},
{
"holder_kbo": null,
"holder_name": "Enkeleta Fazliu",
"scope_categories": [
"publication"
],
"with_substitution": true
},
{
"holder_kbo": null,
"holder_name": "Brent Mastin",
"scope_categories": [
"publication"
],
"with_substitution": true
}
],
"articles_modified": [
{
"summary": "The company\u0027s legal form is confirmed as a soci\u00E9t\u00E9 anonyme, and its name is set to \u0022DeuterOncology\u0022.",
"new_text": "La soci\u00E9t\u00E9 rev\u00EAt la forme d\u0027une soci\u00E9t\u00E9 anonyme. \nElle est d\u00E9nomm\u00E9e \u0022DeuterOncology\u0022.",
"change_kind": "restated",
"article_title": "FORME JURIDIQUE - DENOMINATION",
"article_number": "1"
},
{
"summary": "The company\u0027s registered office is established in the Wallonia region, with the possibility to establish administrative, operational, and branch offices in Belgium or abroad.",
"new_text": "Le si\u00E8ge de la soci\u00E9t\u00E9 est \u00E9tabli en R\u00E9gion wallonne.\nLa soci\u00E9t\u00E9 peut \u00E9tablir, par d\u00E9cision de l\u2019organe d\u0027administration, des si\u00E8ges administratifs, des\nsi\u00E8ges d\u0027exploitation, des succursales et des d\u00E9p\u00F4ts en Belgique ou \u00E0 l\u0027\u00E9tranger.",
"change_kind": "restated",
"article_title": "SIEGE",
"article_number": "2"
},
{
"summary": "The company\u0027s object is comprehensively restated to include research, development, and commercialization of pharmaceutical, veterinary, and biological products, as well as related supplies and personalized medicine.",
"new_text": "La soci\u00E9t\u00E9 a pour objet :\nA/ La recherche scientifique, l\u0027\u00E9tude clinique, les essais, l\u0027analyse et l\u0027\u00E9valuation, le\nd\u00E9veloppement clinique, l\u0027achat, la fabrication, l\u0027octroi de licences ou la prise de licences, la vente,\nl\u0027importation et l\u0027exportation, la location et, en g\u00E9n\u00E9ral, la conclusion de toutes les transactions\npossibles concernant les produits pharmaceutiques, v\u00E9t\u00E9rinaires, biologiques, ",
"change_kind": "restated",
"article_title": "OBJET",
"article_number": "3"
},
{
"summary": "The company exists for an unlimited duration.",
"new_text": "La soci\u00E9t\u00E9 existe pour une dur\u00E9e illimit\u00E9e.",
"change_kind": "restated",
"article_title": "DUREE",
"article_number": "4"
},
{
"summary": "The capital is fixed at \u20AC16,683,478.00, represented by 2,300,342 shares without nominal value, consisting of 1,119,227 Ordinary and 1,181,115 Preferential shares.",
"new_text": "5.1. Capital \u00E9mis\nLe capital est fix\u00E9 \u00E0 seize millions six cent quatre-vingt-trois mille quatre cent septante-huit euros (\u20AC\n16.683.478,00).\nIl est repr\u00E9sent\u00E9 par deux million trois cent mille trois cent quarante-deux (2.300.342) actions, sans\nmention de valeur nominale, dont :\n- un million cent dix-neuf mille deux-cent vingt-sept (1.119.227) Actions Ordinaires ;\n- un million cent quatre-vingt-et-u",
"change_kind": "restated",
"article_title": "CAPITAL",
"article_number": "5"
},
{
"summary": "The company is administered by a board of up to five members, elected by the general meeting, with specific nomination rights for preferential and ordinary shareholders.",
"new_text": "La soci\u00E9t\u00E9 est administr\u00E9e par un conseil d\u2019administration, qui est compos\u00E9 de cinq (5) membres au\nmaximum, nomm\u00E9s par l\u0027assembl\u00E9e g\u00E9n\u00E9rale, et qui est compos\u00E9 comme suit :\n- la majorit\u00E9 des membres (p.e. 3 des 5 membres, 3 des 4 membres ou 2 des 3 membres)\nsont \u00E9lus sur proposition de l\u2019Actionnaire Pr\u00E9f\u00E9rentiel (les Administrateurs Pr\u00E9f\u00E9rentiels) ; et\n- les membres restants sont \u00E9lus sur proposit",
"change_kind": "restated",
"article_title": "COMPOSITION DE L\u2019ORGANE D\u0027ADMINISTRA\u00ACTION",
"article_number": "8"
},
{
"summary": "The board of directors is invested with the widest powers to perform all acts necessary or useful for the realization of the company\u0027s object, with the exception of those reserved by law for the general meeting.",
"new_text": "Le conseil d\u0027administration est investi des pouvoirs les plus \u00E9tendus pour accomplir tous les actes\nn\u00E9cessaires ou utiles \u00E0 la r\u00E9alisation de l\u0027objet de la soci\u00E9t\u00E9, \u00E0 l\u0027exception de ceux que la loi r\u00E9serve \u00E0",
"change_kind": "restated",
"article_title": "POUVOIR DE GESTION \u2013 GESTION JOURNALERE",
"article_number": "10"
},
{
"summary": "The board of directors represents the company towards third parties and in court. The company is also validly represented by two administrators acting jointly, at least one of whom is a Preferential Administrator, with power of substitution.",
"new_text": "Le conseil d\u2019administration repr\u00E9sente la soci\u00E9t\u00E9 \u00E0 l\u2019\u00E9gard des tiers et en justice, en tant que\ndemandeur ou d\u00E9fendeur.\nLa soci\u00E9t\u00E9 est \u00E9galement valablement repr\u00E9sent\u00E9e \u00E0 l\u2019\u00E9gard des tiers et en justice, en tant que",
"change_kind": "restated",
"article_title": "POUVOIR DE REPRESENTATION",
"article_number": "11"
},
{
"summary": "The ordinary general meeting meets on the last Friday of May at 10:00. If this day is a Saturday, Sunday, or holiday, the meeting takes place on the first following working day.",
"new_text": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire se r\u00E9unit le dernier vendredi du mois de mai \u00E0 10 heures. \nSi ce jour est un samedi, un dimanche ou un jour f\u00E9ri\u00E9, l\u0027assembl\u00E9e g\u00E9n\u00E9rale a lieu le premier jour",
"change_kind": "restated",
"article_title": "DATE ASSEMBLEE GENERALE ORDINAIRE - ASSEMBLEE GENERALE SPECIALE /\nEXTRAORDINAIRE",
"article_number": "13"
},
{
"summary": "To be admitted to the general meeting, holders of titles must deposit their (certificates of) titles at the seat or at the designated establishments at least three working days before the date fixed for the meeting, if the convocation requires it.",
"new_text": "Pour \u00EAtre admis \u00E0 l\u0027assembl\u00E9e g\u00E9n\u00E9rale, les d\u00E9tenteurs de titres, qui ont le droit d\u2019\u00EAtre convoqu\u00E9s\nconform\u00E9ment aux dispositions l\u00E9gales applicables, doivent, si la convocation l\u0027exige, au moins trois",
"change_kind": "restated",
"article_title": "ADMISSION \u00C0 L\u2019ASSEMBLEE GENERALE",
"article_number": "16"
},
{
"summary": "Any shareholder may be represented at the general meeting by a proxy, shareholder or not. The powers of attorney must be communicated in writing, by letter or by e-mail or by any other means of communication that materializes in a written document at the recipient.",
"new_text": "Tout actionnaire peut se faire repr\u00E9senter \u00E0 l\u2019assembl\u00E9e g\u00E9n\u00E9rale par un mandataire, actionnaire ou\nnon. Les procurations doivent comporter une signature.\nLes procurations doivent \u00EAtre communiqu\u00E9es par \u00E9crit, par lettre ou par e-mail ou par tout autre",
"change_kind": "restated",
"article_title": "REPRESENTATION",
"article_number": "17"
},
{
"summary": "Each Ordinary share gives the right to one vote, and each Preferential share gives the right to three votes. Shareholders may participate in the general meeting at a distance via an electronic communication means provided by the company.",
"new_text": "Chaque Action Ordinaire donne droit \u00E0 une voix, et chaque Action Pr\u00E9f\u00E9rentielle donne droit \u00E0 trois\nvoix.\nChaque actionnaire peut participer \u00E0 distance \u00E0 l\u0027assembl\u00E9e g\u00E9n\u00E9rale par le biais d\u0027un moyen de",
"change_kind": "restated",
"article_title": "DROIT DE VOTE",
"article_number": "21"
},
{
"summary": "The fiscal year begins on January 1st and ends on December 31st of each year.",
"new_text": "L\u0027exercice social commence le 1er janvier pour se terminer le 31 d\u00E9cembre de chaque ann\u00E9e.",
"change_kind": "restated",
"article_title": "EXERCICE SOCIAL \u2013 COMPTES ANNUELS \u2013 RAPPORT ANNUEL",
"article_number": "23"
},
{
"summary": "If and as long as the law requires, an annual deduction of at least five percent (5%) is made on the net profits of the company for the constitution of the legal reserve.",
"new_text": "Si et aussi longtemps que la loi l\u2019exige, il est effectu\u00E9 annuellement sur les b\u00E9n\u00E9fices nets de la\nsoci\u00E9t\u00E9 un pr\u00E9l\u00E8vement de cinq pourcent (5%) au moins qui est affect\u00E9 \u00E0 la constitution de la r\u00E9serve",
"change_kind": "restated",
"article_title": "REPARTITION DES BENEFICES",
"article_number": "24"
},
{
"summary": "The company can be dissolved at any time by a decision of the general meeting deliberating in the manner required by law, or is dissolved in the cases provided by law. During dissolution with liquidation, one or more liquidators are appointed if necessary by the general meeting.",
"new_text": "26.1. Dissolution et liquidation\nLa soci\u00E9t\u00E9 peut en tout temps \u00EAtre dissoute par d\u00E9cision de l\u0027assembl\u00E9e g\u00E9n\u00E9rale qui d\u00E9lib\u00E8re de la\nmani\u00E8re requise par la loi, ou est dissoute dans les cas pr\u00E9vus par la loi. \nLors de la dissolution avec liquidation, un ou plusieurs liquidateurs sont nomm\u00E9s le cas \u00E9ch\u00E9ant par",
"change_kind": "restated",
"article_title": "DISSOLUTION \u2013 LIQUIDATION - PR\u00C9F\u00C9RENCE DE LIQUIDATION",
"article_number": "26"
},
{
"summary": "In case of a Liquidation Event, the proceeds will be paid as follows: A. The holder of Preferential Shares has the right to receive, before and in preference to all other shareholders, payment of an amount equal to one (1) times the subscription price paid by this holder for the Preferential Shares ",
"new_text": "En cas d\u2019un \u00C9v\u00E9nement de Liquidation (tel que d\u00E9fini ci-dessous), tout produit sera pay\u00E9 comme suit :\nA. Le d\u00E9tenteur d\u0027Actions Pr\u00E9f\u00E9rentielles a le droit de recevoir, avant et de pr\u00E9f\u00E9rence par",
"change_kind": "restated",
"article_title": "PR\u00C9F\u00C9RENCE DE LIQUIDATION",
"article_number": "27"
}
],
"governance_change": {
"organ_kind_after": "collegial",
"organ_kind_before": null,
"admin_delegated_added": [
{
"name": "Newton Biocapital I",
"excluded_powers": []
},
{
"name": "NOSHAQ and Investsud Tech",
"excluded_powers": []
}
],
"representation_rule_after": "twee_gezamenlijk",
"co_signature_threshold_eur": null,
"representation_rule_before": null
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Berquin Notarissen BV/SRL",
"person_name": null,
"org_rep_person_name": null
},
"co_filed_documents": [
"une exp\u00E9dition du proc\u00E8s-verbal",
"huit procurations",
"le texte coordonn\u00E9 des statuts",
"le rapport de l\u0027organe d\u0027administration",
"le rapport du commissaire \u00E9tabli en application de l\u0027article 7:155 du Code des soci\u00E9t\u00E9s et des associations",
"le rapport de l\u0027organe d\u0027administration et le rapport du commissaire \u00E9tabli en application des articles 7:179, \u00A71, deuxi\u00E8me alin\u00E9a et 7:197, \u00A71, deuxi\u00E8me alin\u00E9a du Code des soci\u00E9t\u00E9s et des associations"
],
"shareholder_rights": {
"quorum_rules_changed": true,
"liquidation_preference_text": "En cas d\u2019un \u00C9v\u00E9nement de Liquidation (tel que d\u00E9fini ci-dessous), tout produit sera pay\u00E9 comme suit :\nA. Le d\u00E9tenteur d\u0027Actions Pr\u00E9f\u00E9rentielles a le droit de recevoir, avant et de pr\u00E9f\u00E9rence par rapport \u00E0 tous les autres actionnaires, le paiement d\u0027un montant \u00E9gal \u00E0 une (1) fois le prix de souscription pay\u00E9 par ce d\u00E9tenteur pour les Actions Pr\u00E9f\u00E9rentielles qu\u0027il d\u00E9tient au moment de l\u0027\u00C9v\u00E9nement de Liquidation (la Pr\u00E9f\u00E9rence de Liquidation Pr\u00E9f\u00E9rentielle);\nB. Apr\u00E8s distribution de la Pr\u00E9f\u00E9rence de Liquidation Pr\u00E9f\u00E9rentielle, les d\u00E9tenteurs d\u2019Actions Ordinaires auront le droit de recevoir, le paiement d\u2019un montant conform\u00E9ment aux principes pr\u00E9vus dans la Convention d\u2019Actionnaires (la Pr\u00E9f\u00E9rence de Liquidation Ordinaire) ;\nC. Apr\u00E8s la distribution de la Pr\u00E9f\u00E9rence de Liquidation Pr\u00E9f\u00E9rentielle en faveur du d\u00E9tenteur des Actions Pr\u00E9f\u00E9rentielles et de la Pr\u00E9f\u00E9rence de Liquidation Ordinaire en faveur des d\u00E9tenteurs des Actions Ordinaires, et dans la mesure o\u00F9 il reste des produits de cet \u00C9v\u00E9nement de Liquidation apr\u00E8s la distribution de la Pr\u00E9f\u00E9rence de Liquidation Pr\u00E9f\u00E9rentielle et la Pr\u00E9f\u00E9rence de Liquidation Ordinaire, le produit et les actifs restants seront distribu\u00E9s \u00E0 tous les actionnaires au prorata de leur participation sur la base de l\u0027\u00E9tat de conversion.",
"voorkeurrecht_rules_changed": true,
"aandelenoverdracht_restrictions_changed": true
},
"voorwerp_change_summary": "The object of the company was comprehensively restated to include a broad range of activities related to pharmaceutical, veterinary, and biological products, as well as medical supplies and personalized medicine. The company is authorized to perform all commercial, industrial, real estate, movable, or financial operations directly or indirectly related to its object.",
"capital_structure_change": {
"operations": [
"capital_increase_cash",
"capital_increase_kind",
"share_class_creation",
"share_class_merge",
"share_class_creation"
],
"split_ratio": null,
"shares_after": 2300342,
"shares_before": null,
"capital_after_eur": 16683478.0,
"capital_before_eur": 8598171.15,
"share_classes_after": [
{
"count": 1119227,
"label": "Actions Ordinaires",
"rights_summary": "Voting rights: 1 per share",
"voting_per_share": 1.0
},
{
"count": 1181115,
"label": "Actions Pr\u00E9f\u00E9rentielles",
"rights_summary": "Voting rights: 3 per share",
"voting_per_share": 3.0
}
]
},
"coordinated_text_lineage": null
}22-07-2025 Jean Combalbert reappointed as director
- Jean Combalbert, Bestuurder
Technical details
{
"events": [
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean Combalbert",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Newton Biocapital Partners BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2024-06-01",
"evidence_quote": "A partir du 1 juin 2024, Jean Combalbert sera d\u00E9sign\u00E9 en tant que nouveau repr\u00E9sentant permanent de l\u0027entreprise Newton Biocapital Partners BV, administrateur-personne morale, rempla\u00E7ant Guillaume Oscar C. (Guy) Heynen."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0754.971.388",
"name_full": "DEUTERONCOLOGY",
"legal_form": "SA"
}
}20-06-2024 Capital increase of €1,650,020 to €8,598,171.15
- €6.948.151,15 → €8.598.171,15
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 1650020,
"currency": "EUR",
"after_eur": 8598171.15,
"delta_eur": 1650020.0,
"before_eur": 6948151.15,
"amount_type": "kapitaal_effectief",
"effective_date": "2024-06-06",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital de la Soci\u00E9t\u00E9 \u00E0 concurrence de 1.650.020 EUR, pour le porter de 6.948.151,15 EUR \u00E0 8.598.171,15 EUR.",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0754.971.388",
"name_full": "DEUTERONCOLOGY",
"legal_form": "SA"
}
}26-09-2023 Veerle Catry appointed as statutory auditor
- Veerle Catry, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Veerle Catry",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0431088289",
"name": "B.D.O. R\u00E9viseurs d\u0027Entreprises",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de nommer la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e B.D.O. R\u00E9viseurs d\u0027Entreprises (num\u00E9ro d\u0027entreprise 0431.088.289), situ\u00E9 \u00E0 Rue Da Vinci 9, bo\u00EEte E6, 1930 Zaventem, en tant que commissaire de la Soci\u00E9t\u00E9 pour une dur\u00E9e de trois ann\u00E9es comptables, dont la premi\u00E8re est 2023. Ce"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0754.971.388",
"name_full": "DEUTERONCOLOGY",
"legal_form": "SA"
}
}28-06-2023 Capital increase of €150,000 to €6,948,151.15
- €6.798.151,15 → €6.948.151,15
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 150000,
"currency": "EUR",
"after_eur": 6948151.15,
"delta_eur": 150000.0,
"before_eur": 6798151.15,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-06-20",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital de la Soci\u00E9t\u00E9 \u00E0 concurrence de cent cinquante mille euros (\u20AC 150.000,00), pour le porter de six millions sept cent quatre-vingt-dix-huit mille cent cinquante et un euros et quinze centimes (\u20AC 6.798.151,15) \u00E0 six millions neuf cent quarante-huit mille cent cinquante et un euros et quinze centimes (\u20AC 6.948.151,15).",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0754.971.388",
"name_full": "DEUTERONCOLOGY",
"legal_form": "SA"
}
}02-01-2023 Capital increase of €3,650,004 to €4,715,000.15
- €1.064.996,15 → €4.715.000,15
- 2 kapitaalbewegingen in deze akte
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 3650004,
"currency": "EUR",
"after_eur": 4715000.15,
"delta_eur": 3650004.0,
"before_eur": 1064996.15,
"amount_type": "kapitaal_effectief",
"effective_date": "2022-12-20",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital de la Soci\u00E9t\u00E9 \u00E0 concurrence de 3.650.004 EUR, pour le porter de 1.064.996,15 EUR \u00E0 4.715.000,15 EUR. L\u0027assembl\u00E9e d\u00E9cide que l\u0027augmentation de capital sera r\u00E9alis\u00E9e par apport en num\u00E9raire",
"contribution_type": "cash"
},
{
"kind": "capital_increase",
"amount": 2083151,
"currency": "EUR",
"after_eur": 6798151.15,
"delta_eur": 2083151.0,
"before_eur": 4715000.15,
"amount_type": "kapitaal_effectief",
"effective_date": "2022-12-20",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital de la Soci\u00E9t\u00E9 \u00E0 concurrence de 2.083.151 EUR, pour le porter de 4.715.000,15 EUR \u00E0 6.798.151,15 EUR, par l\u2019\u00E9mission de 163.875 Actions Pr\u00E9f\u00E9rentielles de Classe A et 36.229 Actions Pr\u00E9f\u00E9rentielles de Classe B ... L\u0027assembl\u00E9e d\u00E9cide que l\u0027augmentation du capital sera r\u00E9alis\u00E9e par l\u2019apport par la soci\u00E9t\u00E9 anonyme \u00AB NEWTON BIOCAPITAL I ... de sa cr\u00E9ance certaine, liquide et exigible",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0754.971.388",
"name_full": "DEUTERONCOLOGY",
"legal_form": "SA"
}
}09-08-2022 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": true,
"object_change": false,
"effective_date": "2022-06-29",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0754.971.388",
"name_full": "DEUTERONCOLOGY",
"legal_form": "SA"
},
"signature_regime": "joint_two",
"special_mandates": [
{
"quote": "L\u0027assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 Christoph Michiels, Sander Kevelaerts, Elena Vromans et tout autre avocat de\u0022 Deloitte Legal - Lawyers\u0022... avec droit de substitution, afin d\u0027assurer les formalit\u00E9s aupr\u00E8s d\u0027un guichet d\u0027entreprise en vue d\u0027assurer l\u0027inscription/la modification des donn\u00E9es dans la Banque Carrefour des Entreprises et, le cas \u00E9ch\u00E9ant, aupr\u00E8s de l\u0027Administration de la Taxe sur la Valeur Ajout\u00E9e.",
"holder_kbo": null,
"holder_name": "Deloitte Legal - Lawyers",
"scope_categories": [
"KBO",
"tax",
"filing"
],
"with_substitution": true
}
],
"governance_change": {
"admin_delegated_added": []
}
}25-07-2022 Registered office moved from Geel to Luik
- Oudepostelseweg 1, 2440 Geel → Clos Chanmurly 13, 4000 Luik
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Luik",
"region": "Waals",
"street": "Clos Chanmurly",
"country": "BE",
"postcode": "4000",
"box_number": null,
"street_number": "13"
},
"old_address": {
"city": "Geel",
"region": "Vlaams",
"street": "Oudepostelseweg",
"country": "BE",
"postcode": "2440",
"box_number": null,
"street_number": "1"
},
"effective_date": "2022-06-29",
"evidence_quote": "De vergadering beslist de zetel te verplaatsen naar het Waalse Gewest, te Centre AFINIS BUSINESS CENTER - Clos Chanmurly 13, 4000 Luik."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0754.971.388",
"name_full": "DEUTERONCOLOGY",
"legal_form": "NV"
}
}06-04-2021 2 directors appointed
- Timothy Perera, Dagelijks bestuur
- Gustaaf Van Reet, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "dagelijks_bestuur",
"person": {
"rrn": null,
"name": "Timothy Perera",
"address": null,
"birth_date": null
},
"effective_date": "2021-03-01",
"evidence_quote": "de heer Timothy Perera wonende te Oudepostelseweg 1, 2440 Geel, Belgi\u00EB, te benoemen als dagelijks bestuurder van de Vennootschap en dit met ingang vanaf heden voor een periode van onbepaalde duur."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Gustaaf Van Reet",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "VIZIPHAR Biosciences BV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2021-03-01",
"evidence_quote": "VIZIPHAR Biosciences BV, vertegenwoordigd door haar vaste vertegenwoordiger de heer Gustaaf Van Reet, te benoemen als voorzitter van de raad van bestuur van de Vennootschap en dit met ingang vanaf heden voor een periode van onbepaalde duur."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0754.971.388",
"name_full": "DEUTERONCOLOGY",
"legal_form": "NV"
}
}12-02-2021 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": true,
"effective_date": "2021-02-04",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0754.971.388",
"name_full": "DEUTERONCOLOGY",
"legal_form": "NV"
},
"signature_regime": "joint_two",
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}30-09-2020 Incorporation of a new NV
Technical details
{
"kind": "oprichting",
"seat": "Oudepostelseweg 1, 2440 Geel",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": null,
"name": "PERERA Timothy Pietro Suren",
"niss": null,
"address": "Oudepostelseweg 1, 2440 Geel"
},
"share_class": "naamloze aandelen",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 65000,
"holder_person_name": "PERERA Timothy Pietro Suren",
"is_subscriber_only": true,
"n_shares_subscribed": 65000,
"amount_subscribed_eur": 65000,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 65000,
"subject_company": {
"kbo": "0754.971.388",
"name_full": "DeuterOncology",
"legal_form": "NV"
},
"initial_directors": [],
"incorporation_date": "2020-09-23",
"post_incorporation_mandates": []
}| Legal nameFR | DeuterOncology |